Skip to main content
. 2017 Dec 7;2(23):e95128. doi: 10.1172/jci.insight.95128

Figure 3. 2DG treatment in vivo causes decreased target clearance during MCMV infection.

Figure 3

Female WT C57BL/6 mice were infected with 1 × 105 PFU murine cytomegalovirus (MCMV), treated daily with 2-deoxy-ᴅ-glucose (2DG) or PBS, and analyzed on day 2 after infection. (A) Equal numbers of labeled nontarget splenocytes and target m157-transgenic splenocytes were injected i.v., and target clearance in the spleen was measured 4 hours later (n = 7–12 individuals/group, 2 separate experiments). (B) The number and percentage of NK cells isolated from the spleen or liver (n = 7–8/group, 2 experiments). (C) Flow plots and mean fluorescence intensity (Gzmb MFI) measured by flow cytometry in Ly49H+ (solid) and Ly49H- (hatched) NK cells from the spleen or liver (n = 4/group, representative of 2 experiments). (D) CD107a expression on splenocytes (n = 7–8/group, 2 experiments). Data show mean ± SEM. All statistical analyses are 1-way ANOVA with Tukey’s multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001.